CLIA Kit for Epiregulin (EREG) Rattus norvegicus (Rat) Sandwich CLIA

EPR; ER; Proepiregulin

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Epiregulin (EREG) Packages (Simulation)
  • CLIA Kit for Epiregulin (EREG) Packages (Simulation)
  • CLIA Kit for Epiregulin (EREG) Results demonstration
  • SCB945Ra.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Epiregulin (EREG) and the recovery rates were calculated by comparing the measured value to the expected amount of Epiregulin (EREG) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 90-101 96
EDTA plasma(n=5) 89-96 93
heparin plasma(n=5) 83-98 95

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Epiregulin (EREG) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Epiregulin (EREG) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Epiregulin (EREG) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 94-103% 91-101% 90-97% 91-98%
EDTA plasma(n=5) 83-91% 98-105% 83-91% 90-104%
heparin plasma(n=5) 95-102% 85-103% 80-92% 87-95%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Epiregulin (EREG)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Epiregulin (EREG). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Epiregulin (EREG). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Epiregulin (EREG) level in the sample or standard.;

Citations

  • Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cellsNature: 2012103
  • Aryl hydrocarbon receptor antagonism attenuates growth factor expression, proliferation, and migration in fibroblast-like synoviocytes from patients with rheumatoid arthritis.Pubmed: 24309559
  • The Ah receptor regulates growth factor expression in head and neck squamous cell carcinoma cell linesPubmed:23625689
  • Epiregulin promotes the emergence and proliferation of adult liver progenitor cells.Pubmed:24812054
  • Epiregulin-loaded PLGA nanoparticles increase human keratinocytes proliferation: preliminary datapubmed:27383296
  • Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulationPMC5593575
  • Potential Involvement of the Epidermal Growth Factor Receptor Ligand Epiregulin and Matrix Metalloproteinase-1 in Pathogenesis of Chronic Rhinosinusitispubmed:28398769
  • Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancerPubmed: 30252132
  • Epiregulin is released from intervertebral disks and induces spontaneous activity in pain pathwaysDoi: 10.1097/PR9.0000000000000718
  • Epiregulin enhances odontoblastic differentiation of dental pulp stem cells via activating MAPK signalling pathwayPubmed: 31454111
  • Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived XenograftsPubmed: 31771279
  • Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicinePubmed: 33212364
  • Compromised Cumulus-Oocyte Complex Matrix Organization and Expansion in Women with PCOS34748173
  • MiR-192-5p suppresses M1 macrophage polarization via epiregulin (EREG) downregulation in gouty arthritis34715618

Recommend products